Analytical Methods and Arrays for Use in the Same
AssigneeSenzagen AB
InventorsMalin Lindstedt, Carl A.K. Borrebaeck, Henrik Johansson, Ann-Sofie Albrekt, Andrew Forreryd
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method for identifying agents capable of inducing respiratory sensitization in a mammal and arrays and diagnostic kits for use in such methods. In particular, the methods include measurement of the expression of the biomarkers listed in Table A(i), Table A(ii) and/or Table A(iii) in cells exposed to a test agent.
Claims81
A method for identifying agents capable of inducing respiratory sensitization in a mammal comprising or consisting of the steps of:
- a) exposing a population of dendritic cells or a population of dendritic-like cells to a test agent;
- and
- b) measuring in the cells the expression of one or more biomarker(s) selected from the group defined in Table A(i) and/or Table A(ii);
- wherein the expression in the cells of the one or more biomarkers measured in step (b) is indicative of the respiratory sensitizing effect of the test agent.
The method according to any one of the preceding claims wherein step (b) comprises or consists of measuring the expression of one or more biomarkers defined in Table A(ii) for example, at least 2 or 3 of the biomarkers defined in Table 1A.
The method according to any one of the preceding claims wherein step (b) comprises or consists of measuring the expression of TNFRSF19.
The method according to any one of the preceding claims wherein step (b) comprises or consists of measuring the expression of SNORA74A.
The method according to any one of the preceding claims wherein step (b) comprises or consists of measuring the expression of SPAM1.
The method according to any one of the preceding claims wherein step (b) comprises or consists of measuring the expression of TNFRSF19, SNORA74A and SPAM1.
The method according to any one of the preceding claims wherein step (b) comprises or consists of measuring in step (b) the expression of one or more biomarkers defined in Table A(ii), for example, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341 or 342 of the biomarkers defined in Table A(ii).
The method according to any one of the preceding claims wherein step (b) comprises or consists of measuring the expression of all of the biomarkers defined in Table A(ii).
The method according to any one of the preceding claims wherein step (b) comprises or consists of measuring the expression of one or more of the biomarkers defined in Table A(iii), for example, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43 or 44 of the biomarkers defined in Table A(iii).
The method according to any one of the preceding claims wherein step (b) comprises or consists of measuring the expression of all of the biomarkers defined in Table A(iii).
The method according to any one of the preceding claims wherein step (b) comprises or consists of measuring the expression of all of the biomarkers defined in Table A.
The method according to any one of the preceding claims wherein step (b) comprises measuring the expression of a nucleic acid molecule encoding the one or more biomarker(s).
The method according to any one of the preceding claims wherein measuring the expression of the one or more biomarker(s) in step (b) is performed using one or more binding moieties, each capable of binding selectively to a nucleic acid molecule encoding one of the biomarkers identified in Table A.
The method according to any one of claims 21 to 24 wherein the one or more binding moieties are 5 to 100 nucleotides in length.
The method according to any one of claims 21 to 25 wherein the one or more nucleic acid molecules are 15 to 35 nucleotides in length.
The method according to any one of claims 21 to 26 wherein the binding moiety comprises a detectable moiety.
The method according to any one of the preceding claims wherein step (b) is performed using an array.
The method according to any one of the preceding claims for identifying agents capable of inducing a respiratory hypersensitivity response.
The method according to any one of the preceding claims wherein the hypersensitivity response is a humoral hypersensitivity response.
The method according to any one of the preceding claims for identifying agents capable of inducing respiratory allergy.
The method according to any one of the preceding claims wherein the population of dendritic cells or population of dendritic-like cells is a population of dendritic-like cells.
The method according to any one of the preceding claims wherein the dendritic-like cells are MUTZ-3 cells.
The method according to any one of the preceding claims wherein the method is indicative of the sensitizing potency of the sample to be tested.
Use of two or more biomarkers selected from the group defined in Table A in combination for identifying respiratory hypersensitivity response sensitising agents.
A method of treating or preventing a respiratory type I hypersensitivity reaction (such as respiratory asthma) in a patient comprising the steps of:
- (a) providing one or more test agent that the patient is or has been exposed to;
- (b) determining whether the one or more test agent provided in step (a) is a respiratory sensitizer using a method provided in the first aspect of the present invention;
- and
- (c) where one or more test agent is identified as a respiratory sensitizer, reducing or preventing exposure of the patient to the one or more test agent identified as a respiratory sensitizer and/or providing appropriate treatment for the symptoms of sensitization.
A computer program for operating the method defined in the first aspect of the invention.
A method or use substantially as described herein.
An array, kit or computer program substantially as described herein.
Dependencies are inferred from the claim text.